Moreover, innovation remains a key driver. Eli Lilly is actively testing tirzepatide for indications against MASH and chronic kidney disease and its oral GLP-1 agonist orforglipron is in Phase III trials for obstructive sleep apnea in addition to obesity and type II diabetes.
Novo Nordisk is also exploring new indications for semaglutide, including MASH, and as a potential treatment for Alzheimer’s disease.
According to Evaluate analysts, the field of oncology continues to be another evolving area within the pharmaceutical industry. While traditional cancer treatments remain relevant, there has been a notable shift in R&D focus towards more targeted approaches.
These trials could unlock new treatment options and expand the market for these already successful ADCs.
“They add to the growing body of evidence that domvanalimab…may have a differentiated efficacy, safety and tolerability profile relative to published data from studies with Fc-enabled anti-TIGIT antibodies.”
The ACA currently provides health insurance coverage to over 45 million Americans. Changes to coverage could have ripple effects throughout the healthcare sector, including the pharmaceutical industry, as reduced coverage could lead to decreased demand for certain medications.
If IRA provisions remain in place or are strengthened, they could put downward pressure on drug prices, potentially impacting company revenues and investor returns. Conversely, if these provisions are weakened or repealed, it could provide a boost to the industry. Investors will need to closely observe political developments and any signals regarding the future of the IRA.
Overall, the pharmaceutical industry in 2025 is expected to be characterized by innovation, growth, and transformation. While challenges remain, the industry’s focus on research and development, coupled with advancements in technology and a commitment to patient care, is expected to drive progress and deliver significant benefits to patients worldwide.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Sona Nanotech is a client of the Investing News Network. This article is not paid-for content.
Leave a Reply